EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS‐1 phase 3 trial

David F Mercer iD, Constance Mubekapi-Musadaidzwa, Bitten Kloster, Mark Berner-Hansen, Anna Rydén, Palle Bekker Jeppesen iD

Nutrition in Clinical Practice · 2026-08 · 41 (4) · 1106-1118

DOI: 10.1002/ncp.70109 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrition in Clinical Practice, online erschienen am 12.03.2026. Verfasst von David F Mercer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Quality of Life, Short Bowel Syndrome, Intestinal Failure, Cost of Illness. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was funded by Zealand Pharma, who is also the sponsor of the overall clinical study from which participants were recruited for exit interviews. Zeala….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A randomized, double‐blind, placebo‐controlled trial was conducted to evaluate efficacy and safety of glepaglutide in patients who have short bowel syndrome with intestinal failure (SBS‐IF). At the end of the trial, exit interviews were conducted to explore participants' experiences and to assess the impact of the disease and treatment during the trial.

Methods

Thirty patients from four countries were interviewed over the phone. Data were collected using a semistructured interview manual, and interviews were recorded and transcribed for analysis.

Results

Patients reported that SBS‐IF negatively impacted their lives before the trial, causing loss of freedom, disrupted sleep, limited physical activity, and pain. During the interviews, patients reported that the treatment improved their well‐being across multiple domains. Seventy‐three percent of the patients receiving glepaglutide ( n = 16/22) reported positive changes in health‐related quality of life compared with 25% receiving placebo ( n = 2/8). Twenty‐six patients reported experiencing a reduction in parenteral support (PS) volume. Of these, 21 patients (18 glepaglutide, three placebo) reported a change in overall status, with 94% receiving glepaglutide ( n = 17/18) and 67% ( n = 2/3) receiving the placebo finding this change meaningful. Although descriptive, these findings should be interpreted cautiously given the small number of patients.

Conclusion

During exit interviews, patients receiving glepaglutide reported improvements in well‐being across multiple domains, noting meaningful reductions in PS volume and a reduced impact of SBS‐IF on daily life, which was proportionally greater than in those receiving placebo. These findings underscore the patient‐reported positive experiences of glepaglutide and its beneficial effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeShort Bowel SyndromeIntestinal FailureCost of IllnessGastrointestinal AgentsHumansFemaleMaleDouble-Blind MethodMiddle AgedAdultAgedTreatment OutcomeSymptom BurdenGlucagon-Like Peptide 2

Stichwörter der Autor:innen

SBS‐IFexit interviewintestinal failurequality of lifeshort bowel syndrome

Substanzen

Gastrointestinal AgentsglepaglutideGlucagon-Like Peptide 2

Autor:innen und Institutionen

  • Department of Surgery, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, Nebraska, USA.
  • CLINIGMA, Copenhagen, Denmark.
  • Zealand Pharma, Copenhagen, Denmark.
  • Digestive Disease Centre, Bispebjerg University Hospital of Copenhagen, Copenhagen, Denmark.
  • Rigshospitalet, Department of Digestive Diseases, Transplantation and General Surgery, Section for Intestinal Failure, Copenhagen, Denmark.

ORCID-Profile: David F Mercer, Palle Bekker Jeppesen

Förderung

  • This work was funded by Zealand Pharma, who is also the sponsor of the overall clinical study from which participants were recruited for exit interviews. Zeala…

Zitieren

APA

Mercer, D. F., Mubekapi-Musadaidzwa, C., Kloster, B., Berner-Hansen, M., Rydén, A., & Jeppesen, P. B. (2026). Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS‐1 phase 3 trial. Nutrition in Clinical Practice, 41(4), 1106-1118. https://doi.org/10.1002/ncp.70109

Vancouver

Mercer DF, Mubekapi-Musadaidzwa C, Kloster B, Berner-Hansen M, Rydén A, Jeppesen PB. Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS‐1 phase 3 trial. Nutrition in Clinical Practice. 2026;41(4):1106-1118. doi:10.1002/ncp.70109

BibTeX
@article{Mercer2026,
  author = {Mercer, David F and Mubekapi-Musadaidzwa, Constance and Kloster, Bitten and Berner-Hansen, Mark and Rydén, Anna and Jeppesen, Palle Bekker},
  title = {Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS‐1 phase 3 trial},
  journal = {Nutrition in Clinical Practice},
  year = {2026},
  volume = {41},
  number = {4},
  pages = {1106--1118},
  doi = {10.1002/ncp.70109}
}
Kostenlos starten →